Business Wire

AlbaCore Capital Group Continues to Expand with Three Senior Hires

20.9.2021 12:14:00 EEST | Business Wire | Press release

Share

European credit specialist AlbaCore Capital Group (“AlbaCore”), today announces three senior hires to reinforce its Operations, Business Development and Investor Relations teams.

As part of the growth of the AlbaCore platform, investing across the European credit spectrum with $8.5bn1 AUM, AlbaCore has bolstered its senior executive group. Jenny Fung is appointed as Managing Director of Investor Relations in New York to further expand global investor relationships and our commitment to the region. Tara Mulholland joins as Head of Business Transformation and Micaela Kelley as Deputy Chief Operating Officer to support Matthew Courey, Chief Operating Officer and Founding Partner.

Jenny brings a wealth of financial services experience with 25 years in the industry. She joins from Taconic Capital, a global investment firm, where she was Director of Marketing and Investor Relations for 13 years, and prior to that at Bank of America, AIG and CSFB.

Tara will oversee an operational change programme across the firm, joining with 19 years’ experience from Cheyne Capital where she was a Partner and served as Head of Business Transformation, Chief Administrative Officer and Head of Operations.

Micaela joins with over 11 years of experience as a Chief Operating Officer with alternative funds. She joins from JNE Partners where she served as Partner and Chief Operating Officer following the spin-out from MSD Partners, and previously as Partner and Chief Operating Officer of Observatory Capital Management. Micaela has 17 years prior experience in prime brokerage and credit risk management at Goldman Sachs and Morgan Stanley.

Matthew Courey, Founding Partner and Chief Operating Officer at AlbaCore Capital Group, commented: “We are excited to have Jenny, Tara and Micaela join the AlbaCore team. Their unique backgrounds and depth of experience will continue to drive our business and position our team optimally for the many opportunities ahead”.

David Allen, Managing Partner and Chief Investment Officer at AlbaCore Capital Group added: “I am delighted that such high calibre executives have chosen to join the firm. We are proud of the talented team we have built at AlbaCore with 20 nationalities and a diverse set of backgrounds and experiences. Tara, Micaela and Jenny will further strengthen our ability to deliver for our investors across the credit spectrum”.

Since the start of 2021, AlbaCore has appointed 15 new professionals across its Investment, Investor Relations, Legal and Compliance, Finance, Operations, Systems and Risk teams, including hires from Albourne, Canyon Capital Advisors, CVC Capital Partners, The Carlyle Group, Citi, EQT Partners and Marathon Asset Management Capital taking the total team size to 53 individuals.

- ENDS –

About AlbaCore Capital Group

AlbaCore Capital Group is one of Europe’s leading specialist credit investors focusing on public and private corporate credit markets. The senior investment team have been investing with this hybrid strategy for over a decade2. Founded in 2016, AlbaCore has invested over $17bn3 for global pension funds, sovereign wealth funds, consultants, insurance companies, family offices and endowments.

AlbaCore is focused on consistently outperforming the market in the long term while protecting investor capital. The credit selection process is based on fundamental research with a focus on capital preservation, ESG factors and risk-adjusted returns.

Headquartered in London with offices in New York and Dublin, AlbaCore has a partnership approach with values at the center of the AlbaCore community.

www.AlbaCoreCapitalGroup.com


1 AUM as at 31 July 2021

2 Including period prior to AlbaCore at the Canada Pension Plan Investment Board (“CPPIB”).

3 Invested capital is the sum of all 'buy' trades for all AlbaCore mandates since inception to 31 July 2021, and includes recycled capital and co-investment.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kepler Communications
Charlotte Balbirnie
+44 (0)7989 528421
CBalbirnie@keplercomms.com

Caroline Villiers
+44 (0)7808 585184
CVilliers@keplercomms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye